Clinical and laboratory predictors of effectiveness of background therapy in rheumatoid arthritis


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The evaluation of clinical and laboratory predictors of the effectiveness of combination therapy with methotrexate and infliximab in rheumatoid arthritis (RA) was performed. A 30-week study included 18 patients with RA. It has been established that background anti-inflammatory therapy in combination with genetically engineered biologic drugs leads to a significant improvement in clinical and laboratory indicators (a marked decrease in the of acute phase inflammatory marker levels, normalization of the hemogram) and the quality of life of patients with high RA activity.

Texto integral

Acesso é fechado

Sobre autores

S. Dotsenko

FSBEI HE "Volgograd State Medical University" of RMH

Email: svetlanahime@yandex.ru
Postgraduate Student at the Department of Hospital Therapy, MFT with the course of Clinical Rheumatology DIF

L. Shilova

FSBEI HE "Volgograd State Medical University" of RMH

Bibliografia

  1. Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primar for clinicians. 3rd edition. Amgen Inc. 2002. P. 351.
  2. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. New Engl. J. Med. 2004;350:2167-79.
  3. El-Gabalawy H.S., Lipsky P.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004;4(Suppl. 2):297-301.
  4. Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001;9:7-9.
  5. Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies. Arthritis Res. 2002; 4:S17-24.
  6. Kalden J.R. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Res. 2002;4:34-40.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies